VIVIS, a subsidiary of Neutra Corp (OTCMKTS:NTRR), has signed a letter of intent (LOI) with a clinical research company in Houston that would enable them to test hemp-based cannabinoids for the treatment of COVID-19.
VIVIS plans to work with Mercury Clinical Research to start phase 1 clinical trials on the efficacy of CBD in treating SARS-COVID-2. They might also use the trials to find other uses of ant-inflammation,appetite suppressant, anti-insomnia, pain management, recovery, and other health-related diagnoses.
VIVIS is not the first to conduct a study on the subject. Recent research concluded that cannabidiol could prevent and inhibit SARS-COVID-2. They found that patients who took CBD had a lower incidence of SARS-COVID-2 than others who did not.
About 4.6 million people globally had died from COVID-19 as of September 7, 2021. Of this number, 664,000 people were from the U.S. Although approximately 206 million Americans have received at least one dose of a vaccine, new strains have emerged, leading to more infections. The pandemic has not only had an impact on health but also the economy. The company will be trying to find out if hemp-based products produced by VIVIS can offer a solution.
Market Reaction:
On Monday, NTRR stock fell 3.12% at $0.0031 with more than 164.53 million shares, compared to its average volume of 17.70 million shares. The stock has moved within a range of 0.0030 – 0.0051 after opening the trade at $0.0032.
